KR950700746A - Compositions and Methods for Treating Benign Prostatic Hypertrophy - Google Patents

Compositions and Methods for Treating Benign Prostatic Hypertrophy

Info

Publication number
KR950700746A
KR950700746A KR1019940703522A KR19940703522A KR950700746A KR 950700746 A KR950700746 A KR 950700746A KR 1019940703522 A KR1019940703522 A KR 1019940703522A KR 19940703522 A KR19940703522 A KR 19940703522A KR 950700746 A KR950700746 A KR 950700746A
Authority
KR
South Korea
Prior art keywords
compositions
methods
benign prostatic
prostatic hypertrophy
treating benign
Prior art date
Application number
KR1019940703522A
Other languages
Korean (ko)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700746A publication Critical patent/KR950700746A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
KR1019940703522A 1992-04-02 1994-10-04 Compositions and Methods for Treating Benign Prostatic Hypertrophy KR950700746A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86211792A 1992-04-02 1992-04-02
US99779292A 1992-12-29 1992-12-29
PCT/US1993/003145 WO1993019758A1 (en) 1992-04-02 1993-04-02 Compositions and methods for treating benign prostatic hypertrophy

Publications (1)

Publication Number Publication Date
KR950700746A true KR950700746A (en) 1995-02-20

Family

ID=27127672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703522A KR950700746A (en) 1992-04-02 1994-10-04 Compositions and Methods for Treating Benign Prostatic Hypertrophy

Country Status (8)

Country Link
EP (1) EP0633781A4 (en)
JP (1) JPH07505398A (en)
KR (1) KR950700746A (en)
AU (1) AU668157B2 (en)
CA (1) CA2133440A1 (en)
MX (1) MX9301939A (en)
NZ (1) NZ251658A (en)
WO (1) WO1993019758A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
ES2185666T3 (en) * 1993-09-03 2003-05-01 Smithkline Beecham Corp FORMULATION STABILIZED FOR TABLETS.
US5760054A (en) * 1994-04-14 1998-06-02 Merck & Co., Inc. Alpha IC adrenergic receptor antagonists
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
MX2013002377A (en) 2010-09-02 2013-04-29 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US4963547A (en) * 1988-06-01 1990-10-16 Smithkline Beecham Corporation Alpha-andrenergic receptor antagonists and use thereas
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury

Also Published As

Publication number Publication date
WO1993019758A1 (en) 1993-10-14
MX9301939A (en) 1994-08-31
JPH07505398A (en) 1995-06-15
EP0633781A4 (en) 1995-04-19
EP0633781A1 (en) 1995-01-18
AU668157B2 (en) 1996-04-26
AU3945193A (en) 1993-11-08
CA2133440A1 (en) 1993-10-14
NZ251658A (en) 1996-08-27

Similar Documents

Publication Publication Date Title
NO20003096D0 (en) Compositions and Methods for Treating ADD
EP0667769A4 (en) Use of alpha-1c specific compounds to treat benign prostatic hyperplasia.
IL101243A0 (en) Pharmaceutical compositions for treatment of benign prostatic hyperplasia
DK0925069T3 (en) Use of Cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
EP0611302A4 (en) Methods and compositions for treating allergic reactions.
IS2012B (en) Quinoline and quinazoline compounds useful in the treatment, especially for the treatment of benign prostatic hyperplasia
AU9214398A (en) Compositions and methods for treating water
EP0758196A4 (en) Compositions and methods of treating tumors
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
NO951718L (en) Methods and compositions of (+) doxazosin for the treatment of benign hyperplasia and atherosclerosis
FI965008A (en) Compositions and methods for treating tumors
KR950700746A (en) Compositions and Methods for Treating Benign Prostatic Hypertrophy
EP0462668A3 (en) New 17beta-aminobenzoyl-4-aza-5alpha-androst-1-en-3-ones as benign prostatic hypertrophy agents
FI20020270A (en) 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors
PL342339A1 (en) Novel substituted pyridino-aryl piperazines useful in treating benign prostatic hypertrophy
NO901272D0 (en) COMPOSITION AND PROCEDURE FOR REMOVAL OF SULPHIDS.
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
IT1283124B1 (en) PHARMACEUTICAL FORMS AND COMPOSITIONS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY
PL324172A1 (en) Malatonin agonists for treating mild forms of prostatic hypertrophy
KR950701012A (en) COMPOSITION AND PROCESS FOR TREATING METAL
NO952766L (en) Solvent compositions and methods
ZA922010B (en) Improved method of treatment for benign prostatic hyperplasia
AUPO410796A0 (en) Method of treating benign prostatic hyperplasia
AU6374798A (en) Methods and compositions of (+) doxazosin for the treatment of hypertension and benign prostatic hyperplasia

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid